Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Tumor Lysis Syndrome 1Recurrence 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 40fludarabine 36fludarabine phosphate 28Tacrolimus 20Whole-Body Irradiation 18Mycophenolic Acid 18Busulfan 18Melphalan 16thymoglobulin 14Rituximab 13Antilymphocyte Serum 12venetoclax 11Thiotepa 10Nivolumab 9Methotrexate 9Granulocyte Colony-Stimulating Factor 9Stem Cell Transplantation 8Peripheral Blood Stem Cell Transplantation 8Cyclosporine 8trametinib 7Sirolimus 7Cytarabine 7Azacitidine 7AP 1903 reagent 7Filgrastim 6Dexamethasone 6aldesleukin 5Mesna 5Ipilimumab 5Interleukin-2 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × AZD0466 × Lymphoid × Clear all
NCT04214093 2023-08-02

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

AstraZeneca

Phase 1 Terminated
9 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Recurrence, Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡